NCT05451862 (HOMIE-166) is a NA clinical trial of Holmium-166 treatment in Hepatocellular Carcinoma, sponsored by Terumo Europe N.V..

Who is sponsoring NCT05451862?

NCT05451862 is sponsored by Terumo Europe N.V..

What drugs are being tested in NCT05451862?

Interventions in NCT05451862: Holmium-166 treatment, Holmium-166 work-up.

What condition does NCT05451862 study?

NCT05451862 studies Hepatocellular Carcinoma.

Is NCT05451862 still recruiting?

NCT05451862 is currently terminated. Last updated 26 August 2025.

Last reviewed 2025-08-26 · How we verify

NCT05451862: HOMIE-166

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

Terminated NA Last updated 26 August 2025

What this trial tests

NA trial testing Holmium-166 treatment in Hepatocellular Carcinoma in 6 participants. Terminated before completion.

Timeline

21 August 2023

Primary endpoint
27 May 2025

27 May 2025

Quick facts

Lead sponsor	Terumo Europe N.V.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	21 August 2023
Primary completion	27 May 2025
Estimated completion	27 May 2025
Sites	2 locations across Germany

Drugs / interventions tested

Holmium-166 treatment
Holmium-166 work-up

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Terumo Europe N.V.

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Overview of Ongoing Clinical Trials on Radioembolization.
Fabritius MP, Ricke J. · · 2022 · cited 7× · PMID 36184696 · DOI 10.1007/s00270-022-03270-4

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Terumo Europe N.V. trials

Trials by the same sponsor.

NCT05911633 — BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) · NA · recruiting
NCT05705973 — Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients · active not recruiting
NCT05111795 — Holmium-166 Retrospective Collection of Real-World Data · completed
NCT05027698 — Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study · completed
NCT04546477 — Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05451862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Terumo Europe N.V.
Last refreshed: 26 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05451862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing